Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Disease area: Airway diseases

Abstract

Introduction: Steroid-resistant (SR) asthma represents a significant clinical and economic burden. The mechanisms which drive SR asthma are unknown, but respiratory infections have been implicated in the development of disease. Infections increase oxidative stress in the lung and SR asthma is associated with defective antioxidant responses and increased oxidative stress. Hypotheses: Respiratory infections induce changes in the asthmatic airway that increase oxidative stress and contribute to dysregulated antioxidant responses which play a crucial role in the development of SR asthma. Aim: To determine the effects of antioxidant therapy on oxidative stress, inflammation and airways hyper-responsiveness (AHR) in a murine model of Chlamydia-induced SR asthma. Methods: Oxidative stress was measured in our established model of Chlamydia-induced SR allergic airways disease (AAD) using 3-nitrotyrosine and 8-isoprostane assays. The effects of treatment with vitamin E or an NRF2 activator on oxidative stress, inflammation and AHR in SRAAD were assessed compared to dexamethasone (DEX). Results: We show that oxidative stress responses are increased in Chlamydia-induced SRAAD compared to controls with steroid-sensitive AAD. Oxidative stress responses in SRAAD are not affected by DEX. Vitamin E treatment alone reduces oxidative stress and, when combined with DEX, suppresses oxidative stress, inflammation and AHR, in SRAAD. Treatment with the NRF2 activator suppresses all features of SRAAD in the absence of DEX. Conclusions: SRAAD is associated with increased oxidative stress that are resistant to steroids. Our findings suggest that antioxidant therapy may be appropriate for SR asthma especially when combined with steroid therapy.


Rating:

Share or cite this content

Citations should be made in the following way:
James Pinkerton (New Lambton Heights, Australia), James Pinkerton, Richard Kim, Ama-Tawiah Essilfie, Brittany Rae, Jemma Mayall, Md. Khadem Ali, Malcolm Starkey, Lisa Wood, Shyam Biswal, Jay Horvat, Philip Hansbro. Investigating antioxidant therapy for steroid-resistant asthma. Eur Respir J 2016; 48: Suppl. 60, 570

Member's Comments

No comment yet.

Related content which might interest you: Study of antioxidant use in patients with asthma exacerbations Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Characterisation of a steroid-insensitive severe asthma model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Achievement of asthma control in patients with cold airway hyperresponsiveness at different variants of basic therapy Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Use of β-blockers and the risk of asthma exacerbations Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Small airways targeting of inhaled steroids for severe therapy resistant asthma in children Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 When needed use of inhaled steroids in children with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Antioxidant efficiency in the treatment of asthma exacerbations Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Adherence to the treatment of patients with bronchial asthma Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Acute exacerbations of asthma in Barcelona, the recent experience Source: Annual Congress 2013 –Epidemiology of asthma Year: 2013 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016